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aortoiliac occlusive disease
Bibombe P. Mwipatayi, Shannon Thomas, Jackie Wong, Suzanna E. L.
Temple, Vikram Vijayan, Mark Jackson, Sally A. Burrows, On behalf of the
Covered Versus Balloon Expandable Stent Trial (COBEST) Co-investigators
Objective: This trial was conducted to determine if covered stents offer
a patency advantage over bare-metal stents in the treatment of aortoiliac
arterial occlusive disease.
Methods: The Covered Versus Balloon Expandable Stent Trial (COBEST),
a prospective, multicenter, randomized controlled trial, was performed
involving 168 iliac arteries in 125 patients with severe aortoiliac occlusive
disease who were randomly assigned to receive a covered balloon-expand-
able stent or bare-metal stent. Patient demographic data, clinical signs
and symptoms, TransAtlantic Inter-Society Consensus (TASC) classification,
and preprocedure and postprocedure ankle-brachial index measurements
were recorded. The primary end points included freedom from binary reste-
nosis and stent occlusion of the treated area, as determined by ultrasound
imaging or quantitative visual angiography, or both. Postprocedural follow-
up was at 1, 6, 12, and 18 months.
Results: Aortoiliac lesions treated with a covered stent were significantly
more likely to remain free from binary restenosis than those that were
treated with a bare-metal stent (hazard ratio [HR], 0.35; 95% confidence
interval (CI), 0.15-0.82; P = .02). Freedom from occlusion was also higher
in lesions treated with covered stents than in those treated with a bare-
metal stent (HR, 0.28; 95% CI, 0.07-1.09); however, this did not reach statis-
tical significance (P = .07). Subgroup analyses demonstrated a significant
difference in freedom from binary restenosis for covered stents in TASC C
and D lesions compared with a bare stent (HR, 0.136; 95% CI, 0.042-
0.442). This difference was not demonstrated for TASC B lesions (HR,
0.748; 95% CI, 0.235-2.386).
Conclusions: COBEST demonstrates covered and bare-metal stents produce
similar and acceptable results for TASC B lesions. However, covered stents
perform better for TASC C and D lesions than bare stents in longer-term
patency and clinical outcome.Endovascular treatment of acute aortic syndrome
Rachel E. Clough, Kevin Mani, Oliver T. Lyons, Rachel E. Bell, Hany A. Zayed,
Matthew Waltham, Tom W. Carrell, Peter R. Taylor
Background: The term acute aortic syndrome (AAS) encompasses a range of
conditions that have a risk of imminent aortic rupture and where delays in
treatment result in increased mortality. Endovascular treatment offers an
attractive alternative to open surgery but little is known about the durability
of the repair and the factors that predict mortality.
Methods: Prospective data were collected for a cohort of 110 consecutive
patients with endovascular treatment for AAS. Patient and procedural char-
acteristics were related to short- and midterm outcome using multivariate
logistic regression analysis.* Full articles available online at www.jvascsurg.org
1078e5884/$36.00
doi:10.1016/S1078-5884(11)00687-3Results: There were 75 men and 35 women with a median age of 68 (range
57-76) years. The pathologies treated were acute dissection (35), symptom-
atic aneurysm (32), infected aneurysm (18), transection (12), chronic
dissection (9), penetrating ulcer (3), and intramural hematoma (1).
Thirty-day mortality was 12.7% and this was associated with hypotension
(odds ratio [OR], 5.25), use of general anesthetic (OR, 5.23), long proce-
dure duration (OR, 2.03), and increasing age (OR, 1.07). The causes of
death were aortic rupture (4), myocardial infarction (4), stroke (3), and
multisystem organ failure (3). The stroke and paraplegia rates were 7.3%
and 6.4%, respectively. The 1-year survival was 81% and the 5-year survival
63%. Secondary procedures were required in 13 (11.8%) patients. Factors
associated with death at 1 year were presence of an aortic fistula (OR,
9.78), perioperative stroke (OR, 5.87), and use of general anesthetic (OR,
3.76); and at 5 years were aortic fistula (OR, 12.31) and increasing age
(OR, 1.06).
Conclusions: Acute aortic syndrome carries significant early and late
mortality. Emergency endovascular repair offers a minimally invasive treat-
ment option associated with acceptable short and midterm results.
Continued surveillance is important as secondary procedures and aortic-
related deaths continue to occur throughout the follow-up period.Simultaneous thoracic endovascular aortic repair and endovascular aortic
repair is feasible with minimal morbidity and mortality
Melissa L. Kirkwood, Alberto Pochettino, Ronald M. Fairman, Benjamin M.
Jackson, Grace J. Wang, Wilson Y. Szeto, Joseph E. Bavaria, Edward Y. Woo
Objective: To determine the results of simultaneous thoracic endovascular
aortic repair (TEVAR) and endovascular aneurysm repair (EVAR).
Methods: Records were retrospectively reviewed. Eight patients underwent
simultaneous TEVAR and EVAR between 1999 and 2010 at a single center. All
patients had concomitant thoracic and abdominal aortic disease (aneurysms,
penatrating aortic ulcers). Ranges for the thoracic and abdominal aneurysm
diameters were 6.0 to 9.1 cm and 5.0 to 7.6 cm, respectively. Four patients
were treated emergently, and the remainder had indications for simulta-
neous repair. The mean age was 72 years (six males). All patients had signif-
icant comorbidities.
Results: Average procedural time was 173 minutes  25 minutes. Spinal
drainage and neuromonitoring was used in all cases. Thoracic endovascular
aortic repair (TEVAR) was performed prior to EVAR. Three patients required
left subclavian coverage and four patients had full coverage of the thoracic
aorta. Only one patient had internal iliac artery (unilateral) coverage. One
patient was lost to follow-up 6 weeks following discharge. The remainder
were followed between 4 and 77 months postoperatively. No patients
developed acute myocardial infarction, acute renal failure, or neurologic
complications, including permanent paralysis or stroke. One patient devel-
oped transient lower extremity weakness that resolved with blood pressure
augmentation. Mean blood loss was 325 mL  137 mL. The average inten-
sive care unit and hospital stay was 3 days and 8 days, respectively. In
follow-up, one patient developed a type II endoleak that was successfully
embolized.
Conclusion: Combined TEVAR and EVAR can be performed successfully with
minimal morbidity and mortality. In particular, in this limited series of eight
854 Abstractspatients, there have been no occurrences of lower extremity paralysis or
renal failure despite a high proportion of emergent cases. When anatomi-
cally feasible, simultaneous TEVAR and EVAR can be considered as a viable
alternative to staged or hybrid repair.Defining the type of surgeon volume that influences the outcomes for
open abdominal aortic aneurysm repair
J. Gregory Modrall, Eric B. Rosero, Jayer Chung, Frank R. Arko, R. James
Valentine, G. Patrick Clagett, Carlos H. Timaran
Objective: Prior studies have reported improved clinical outcomes with
higher surgeon volume, which is assumed to be a product of the surgeon’s
experience with the index operation. We hypothesized that composite
surgeon volume is an important determinant of outcome. We tested this
hypothesis by comparing the impact of operation-specific surgeon volume
versus composite surgeon volume on surgical outcomes, using open abdom-
inal aortic aneurysm (AAA) repair as the index operation.
Methods: The Nationwide Inpatient Sample was analyzed to identify
patients undergoing open AAA repairs for 2000 to 2008. Surgeons were strat-
ified into deciles based on annual volume of open AAA repairs (“operation-
specific volume”) and overall volume of open vascular operations
(“composite volume”). Composite volume was defined by the sum of several
open vascular operations: carotid endarterectomy, aortobifemoral bypass,
femoral-popliteal bypass, and femoral-tibial bypass. Multiple logistic regres-
sion analyses were used to examine the relationship between surgeon
volume and in-hospital mortality for open AAA repair, adjusting for both
patient and hospital characteristics.
Results: Between 2000 and 2008, an estimated 111,533 (95% confidence
interval [CI], 102,296-121,232) elective open AAA repairs were performed
nationwide by 6,857 surgeons. The crude in-hospital mortality rate over
the study period was 6.1% (95% CI, 5.6%-6.5%). The mean number of open
AAA repairs performed annually was 2.4 operations per surgeon. The mean
composite volume was 5.3 operations annually. As expected, in-hospital
mortality for open AAA repair decreased with increasing volume of open
AAA repairs performed by a surgeon. Mortality rates for the lowest and high-
est deciles of surgeon volume were 10.2% and 4.5%, respectively (P < .0001).
A similar pattern was observed for composite surgeon volume, as the
mortality rates for the lowest and highest deciles of composite volume
were 9.8% and 4.8%, respectively (P < .0001). After adjusting for patient
and hospital characteristics, increasing composite surgeon volume remained
a significant predictor of lower in-hospital mortality for open AAA repair
(odds ratio, 0.994; 95% CI, .992-.996; P < .0001), whereas increasing volume
of AAA repairs per surgeon did not predict in-hospital deaths.
Conclusions: The current study suggests that composite surgeon volu-
mednot operation-specific volumedis a key determinant of in-hospital
mortality for open AAA repair. This finding needs to be considered for future
credentialing of surgeons.Early results and lessons learned from a multicenter, randomized,
double-blind trial of bone marrow aspirate concentrate in critical limb
ischemia
Mark D. Iafrati, John W. Hallett, George Geils, Gregory Pearl, Alan Lumsden,
Eric Peden, Dennis Bandyk, K.S. Vijayaraghava, R. Radhakrishnan, Enrico
Ascher, Anil Hingorani, Sean Roddy
Objectives: Despite advances in endovascular therapies, critical limb
ischemia (CLI) continues to be associated with high morbidity and mortality.
Patients without direct revascularization options have the worst outcomes.
We sought to explore the feasibility of conducting a definitive trial of
a bone marrow-derived cellular therapy for CLI in this “no option”
population.
Methods: A pilot, multicenter, prospective, randomized, double-blind,
placebo-controlled trial for “no option” CLI patients was performed. The
therapy consisted of bone marrow aspirate concentrate (BMAC), prepared
using a point of service centrifugation technique and injected percutane-
ously in 40 injections to the affected limb. Patients were randomized to
BMAC or sham injections (dilute blood). We are reporting the 12-week data.
Results: Forty-eight patients were enrolled. The mean age was 69.5 years
(range, 42-93 years). Males predominated (68%). Diabetes was present in
50%. Tissue loss (Rutherford 5) was present in 30 patients (62.5%), and 18
(37.5%) had rest pain without tissue loss (Rutherford 4). Patients weredeemed unsuitable for conventional revascularization based on multiple
prior failed revascularization efforts (24 [50%]), poor distal targets (43
[89.6%]), and medical risk (six [12.5%]). Thirty-four patients were treated
with BMAC and 14 with sham injections. There were no adverse events
attributed to the injections. Renal function was not affected. Effective
blinding was confirmed; blinding index of 61% to 85%. Subjective and objec-
tive outcome measures were effectively obtained with the exception of
treadmill walking times, which could only be obtained at baseline and
follow-up in 15 of 48 subjects. This pilot study was not powered to demon-
strate statistical significance but did demonstrate favorable trends for BMAC
versus control in major amputations (17.6% vs 28.6%), improved pain (44% vs
25%), improved ankle brachial index (ABI; 32.4% vs 7.1%), improved Ruther-
ford classification (35.3% vs 14.3%), and quality-of-life scoring better for
BMAC in six of eight domains.
Conclusions: In this multicenter, randomized, double-blind, placebo-
controlled trial of autologous bone marrow cell therapy for CLI, the therapy
was well tolerated without significant adverse events. The BMAC group
demonstrated trends toward improvement in amputation, pain, quality of
life, Rutherford classification, and ABI when compared with controls. This
pilot allowed us to identify several areas for improvement for future trials
and CLI studies. These recommendations include elimination of treadmill
testing, stratification by Rutherford class, and more liberal inclusion of
patients with renal insufficiency. Our strongest recommendation is that
CLI studies that include Rutherford 4 patients should incorporate a composite
endpoint reflecting pain and quality of life.Early results of a highly selective algorithm for surgery on patients with
neurogenic thoracic outlet syndrome
Venita Chandra, Cornelius Olcott, Jason T. Lee
Objective: Neurogenic thoracic outlet syndrome (nTOS) encompasses a wide
spectrum of disabling symptoms that are often vague and difficult to diag-
nose and treat. We developed and prospectively analyzed a treatment algo-
rithm for nTOS utilizing objective disability criteria, thoracic outlet
syndrome (TOS)-specific physical therapy, radiographic evaluation of the
thoracic outlet, and selective surgical decompression.
Methods: Patients treated for nTOS from 2000-2009 were reviewed (n = 93).
In period 1, most patients were offered surgery with documentation of
appropriate symptoms. A prospective observational study began in 2007
(period 2) and was aimed at determining which patients benefited most
from surgical intervention. Evaluation began with a validated mini-Quick-
DASH (QD) quality-of-life scale (0-100, 100 = worse) and duplex imaging of
the thoracic outlet. Patients then participated in TOS-specific physical
therapy (PT) for 2 to 4 months and were offered surgery based on response
to PT and improvement in symptoms.
Results: Thirty-four patients underwent first rib resection in period 1 (68%
female, mean age 39, 18% athletes, 15% workers comp). In operated
patients undergoing duplex imaging, 47% showed compression of their
thoracic outlet arterial flow on provocative positioning. Based on subjec-
tive improvement of symptoms, 56% of patients at 1 year had a positive
outcome. In period 2 during the prospective cohort, 59 consecutive
patients were evaluated for nTOS (64% female, mean age 36, 32% athletes,
12% workers comp) with a mean pre-PT QD disability score of 55.1. All
patients were prescribed PT, and 24 (41%) were eventually offered surgical
decompression based on compliance with PT, interval improvement on QD
score, and duplex compression of the thoracic outlet. Twenty-one patients
underwent surgery (SURG group) consisting of first rib resection, middle
and anterior scalenectomy, and brachial plexus neurolysis. There were
significant differences between the SURG and non-SURG cohorts with
respect to age, participation in competitive athletics, history of trauma,
and symptom improvement with PT. At 1-year follow-up, 90% of patients
expressed symptomatic improvement with the mean post-op QD disability
score decreasing to 24.9 (P = .005) and 1-year QD scores improving down
to 20.5 (P = .014).
Conclusions: This highly-selective algorithm for nTOS surgery leads to
improvement in overall success rates documented subjectively and objec-
tively. Compliance with TOS-specific PT, improvement in QD scores after
PT, young age, and competitive athletics are associated with improved
surgical outcomes. Long-term follow-up will be necessary to document sus-
tained symptom relief and to determine who the optimal surgical candidates
are.
Abstracts 855Basilic vein transposition versus biosynthetic prosthesis as vascular access
for hemodialysis
Massimo Morosetti, Silvia Cipriani, Sara Dominijanni, Giovanni Pisani,
Daniele Frattarelli, Fabrizio Bruno
Background: Vascular access (VA) complications account for a significant
number of hospital admissions in dialysis and have substantial costs. A
native arteriovenous fistula (AVF) cannot be successfully obtained in all
patients. At our center, we established an autogenous brachial-basilic
AVF (BBAVF) in the upper arm in patients with a failed forearm fistula
or with superficial vessels that were unsuitable for preparing a good
site for VA. In most of these patients, we resort to prosthetic materials
for creating a functioning VA as the last strategy. The present study
compared the outcomes of BBAVF and AV graft (AVG) in patients under-
going long-term hemodialysis in whom there was no other possibility of
creating a VA.
Methods: We analyzed 57 complex patients, 27 randomized to receive AVG
and 30 randomized to BBAVF, between 2002 and 2008. The Omniflow II
Vascular Prosthesis (Bio Nova International Pty Ltd, North Melbourne, VIC,
Australia), the latest-generation collagen-polyester composite, was used
to create the prosthetic VA. Primary patency (PP) and secondary patency
(SP) rates were calculated using the Kaplan-Meier test. The log-rank test
was used to compare PP and SP rates of the single VA.
Results: Length of hospital admission time, total intervention time, and
mean interval to the first venipuncture for dialysis were longer for BBAVF.
In the early postoperative period, patients who received BBAVF had a compli-
cation rate similar to those who received AVG; however, patients who
received AVG showed a higher rate of long-term adverse events. PP and SP
rates were higher for BBAVF than for AVG, although this was not statistically
significant for SP.
Conclusions: Our results show that BBAVF should be the first choice in
patients with a good life expectancy and who can rely on an available
temporary VA. However, given the shorter time to use, AVG could be an
alternative in patients with compromised clinical conditions and in whoma temporary VA is not reliable, considering that the long-term outcome
may be considered beneficial regardless.Thrombolysis for acute occlusion of the superior mesenteric artery
Steinarr Bjo¨rnsson, Martin Bjo¨rck, Tomas Block, Timothy Resch, Stefan
Acosta
Background: This study evaluated the incidence, complications, and
outcome of local intra-arterial thrombolytic therapy for acute superior
mesenteric artery (SMA) occlusion in Sweden.
Methods: Patients undergoing local intra-arterial thrombolytic therapy for
acute SMA occlusion were identified in the Swedish Vascular Registry (SWED-
VASC) between 1987 and 2009. Patient data were retrieved in a structured
protocol by local vascular surgeons at each participating hospital.
Results: Included were 34 patients (20 women) from 12 hospitals. Median
age was 78 years. The first patient was treated in 1997, and the annual
number of patients undergoing thrombolysis increased continuously from
2004 to 2009. Twenty-eight patients (82%) had embolic occlusion. No
patients (0%) had acute peritonitis, and one (3%) had bloody stools at admis-
sion. Thirty-two patients (94%) were diagnosed by computed tomography
with intravenous contrast enhancement. The median dose of alteplase was
20 mg (interquartile range, 11.6-34.0). Successful thrombolysis was achieved
in 30 patients (88%). Initial adjunctive aspiration thromboembolectomy was
performed in 10 patients. There were six self-limiting bleeding complica-
tions; one from the gastrointestinal tract. Thirteen explorative laparoto-
mies, 10 repeat laparotomies, and eight bowel resections were performed.
The in-hospital mortality rate was 26% (9 of 34). Age was not associated
with in-hospital death (P = .42). Successful thrombolysis was associated
with decreased mortality (P = .048).
Conclusion: Local thrombolysis for acute SMA occlusion is a minimally inva-
sive and effective treatment alternative in a select group of patients without
peritonitis. The few technique-related complications were mild.
